Figure 7. Nilotinib inhibits DDR1 invasive activity of patient‐derived CRC cells.

• A
  Patients with CRC showing high DDR1 expression have shorter progression‐free survival (PFS) and overall survival (OS). Kaplan–Meier analysis using data from 143 patients with stage IV CRC subdivided according to the tumour DDR1 expression level (high/low).
• B
  Increased DDR1 activity in metastatic nodules from patients with CRC. DDR1 activity was evaluated based on the relative DDR1 tyrosine phosphorylation level measured by immunoprecipitation (IP) followed by Western blotting of protein lysates of matched healthy tissue, primary tumour and metastatic lesions from 18 patients with CRC. A representative example for one patient (upper panels) and the relative level of DDR1 tyrosine phosphorylation in each patient quantified by ImageJ (lower histogram) are shown (mean ± SEM; *P < 0.05 Student's t‐test).
• C
  DDR1 activity in patient‐derived CRC lines stimulated or not with collagen I (40 μg/ml for 18 h) and incubated or not with 100 nM nilotinib (red asterisks indicate DDR1 activation).
• D, E
  DDR1 invasive activity in patient‐derived CRC lines. Cell invasion was assessed in Boyden chambers after incubation with the indicated doses of nilotinib (D) or transfection with the indicated siRNAs (mean ± SEM; left panels n = 3 and right panels n = 6; *P < 0.05; **P < 0.01 Student's t‐test). (E) Level of DDR1 depletion upon siRNA transfection.
• F
  DDR1 signalling in patient‐derived CRC cell lines stimulated or not with collagen I (40 μg/ml for 18 h) and treated or not with nilotinib (100 nM) as shown.
• G, H
  DDR1 invasive activity in patient‐derived CRC cell lines. Cell invasion was assessed in Boyden chambers after incubation with the indicated doses of nilotinib (G) or transfection with the indicated siRNAs (mean ± SEM; n = 4; *P < 0.05; **P < 0.01 Student's t‐test). (H) Level of DDR1 depletion upon siRNA transfection.
• I
  Nilotinib inhibits metastatic activity of CPP30 cells. After inoculation of CPP cells in the spleen, nude mice (n = 10/group) were treated daily with DMSO or 50 mg/kg nilotinib (i.p.) as indicated, starting at day 6 post‐injection. After 49 days, livers were removed. A representative image of liver for each group and the metastatic index of each animal are shown (mean ± SEM; *P < 0.05 Student's t‐test).

Source data are available online for this figure.